All In Biotech

Drug Trial Radar · NCT05150691

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303/BNT323 in Patients With Advanced/Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 796 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

796

Planned (sponsor's estimate)

Start

Jan 31, 2022

Primary completion

Aug 2027

Study completion Oct 2027

Sponsor

Lead sponsor
DualityBio Inc.Industry
Sponsor type
Industry
Collaborators
BioNTech SE
First posted
Dec 9, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.

Conditions

  • HER2-positive Advanced Solid Tumor

Interventions

  • DB-1303/BNT323Biological

    Administered IV

  • Pertuzumab InjectionDrug

    Administered IV

  • RitonavirDrug

    Administered oral

  • ItraconazoleDrug

    Administered oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Percentage of Participants with Dose-Limiting Toxicities (DLTs) as assessed by CTCAE v5.0.Time frame: up to 21 days after C1D1
  2. Phase 1: Percentage of participants with AEs in Part 1 graded according to NCI CTCAE v5.0Time frame: Up to Safety Follow-Up visit, approximately 35 days post-treatment
  3. Phase 1: Percentage of Participants with Serious Adverse Events (SAEs) as assessed by CTCAE v5.0.Time frame: Up to follow-up period, approximately 1 year post-treatment
  4. Phase 1: Maximum Tolerated Dose (MTD) of DB-1303Time frame: Up to Safety Follow-Up visit, approximately 35 days post-treatment
  5. Phase 1: Recommended Phase 2 Dose (RP2D) of DB-1303Time frame: Up to Safety Follow-Up visit, approximately 35 days post-treatment
  6. Percentage of participants with AEs in Part 2 graded according to NCI CTCAE v5.0Time frame: Up to follow-up period, approximately 1 year post-treatment
  7. Phase 2: Percentage participants with Serious Adverse Events (SAEs) as assessed by CTCAE v5.0.Time frame: Up to follow-up period, approximately 1 year post-treatment
  8. Phase 2: Percentage of Objective Response Rate (ORR) as assessed by RECIST 1.1.Time frame: Up to follow-up period, approximately 1 year post-treatment
  9. Phase 2 (Dose Expansion 10 only): To evaluate the effect of ritonavir on DB-1303 and P1003 PK in subjects with HER2-expressing, HER2-amplified, or HER2-mutated advanced solid malignant tumorsTime frame: up to safety follow-up visit, approx. 35 days post-treatment
  10. Phase 2 (Dose Expansion 10 only): To evaluate the effect of itraconazole on DB-1303 and P1003 PK in subjects with HER2-expressing, HER2-amplified, or HER2-mutated advanced solid malignant tumors.Time frame: up to safety follow-up visit, approx. 35 days post-treatment

Locations

102 sites in 6 countries. Site status is shown where the registry gives one.

  • Helios Clinical Research

    Cerritos, California · Active not recruiting

  • California Research Institute

    Los Angeles, California · Active not recruiting

  • Sharp Memorial Hospital

    San Diego, California · Active not recruiting

  • Washington Cancer Institute at MedStar Washington Hospital Center

    Washington D.C., District of Columbia · Active not recruiting

  • Advanced Research LLC

    Coral Springs, Florida · Active not recruiting

  • The Oncology Institute of Hope and Innovation

    Lakeland, Florida · Active not recruiting

  • D&H Cancer Research Center LLC

    Margate, Florida · Active not recruiting

  • HCA Mercy Hospital

    Miami, Florida · Withdrawn

  • BRCR Medical Center Inc.

    Plantation, Florida · Active not recruiting

  • BRCR Medical Center Inc.

    Tamarac, Florida · Active not recruiting

  • Southeastern Regional Medical Center, LLC

    Newnan, Georgia · Active not recruiting

  • Kapi'olani Medical Center for Women and Children

    Honolulu, Hawaii · Active not recruiting

  • University of Chicago

    Chicago, Illinois · Active not recruiting

  • Women's Cancer Care

    Covington, Louisiana · Withdrawn

  • Holy Cross Hospital

    Silver Spring, Maryland · Withdrawn

  • Massachusetts General Hospital

    Boston, Massachusetts · Active not recruiting

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts · Active not recruiting

  • Profound Research LLC/Michigan Hematology & Oncology Consultants

    Dearborn, Michigan · Withdrawn

  • David C. Pratt Cancer Center

    St Louis, Missouri · Active not recruiting

  • Women's Cancer Center of Nevada

    Las Vegas, Nevada · Withdrawn

  • Northwell Health

    Lake Success, New York · Withdrawn

  • Laura & Isaac Perlmutter Cancer Center at NYC Langone Health

    New York, New York · Active not recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Active not recruiting

  • North Shore Hematology Oncology Associate P.C. DBA New York Cancer and Blood Specialists

    Shirley, New York · Active not recruiting

  • Regional Medical Oncology Center

    Wilson, North Carolina · Withdrawn

  • Gabrail Cancer Center

    Canton, Ohio · Active not recruiting

  • University of Oklahoma

    Oklahoma City, Oklahoma · Active not recruiting

  • Rittenhouse Hematology Oncology

    Philadelphia, Pennsylvania · Withdrawn

  • Thomas Jefferson University

    Philadelphia, Pennsylvania · Active not recruiting

  • AHN West Penn Hospital

    Pittsburgh, Pennsylvania · Active not recruiting

  • Tennessee Oncology

    Nashville, Tennessee · Active not recruiting

  • Clinical Trial Network

    Houston, Texas · Withdrawn

  • Oncology and Hematology of South Texas, PA

    Laredo, Texas · Active not recruiting

  • NEXT Virginia

    Fairfax, Virginia · Active not recruiting

  • Swedish Cancer Institute

    Seattle, Washington · Active not recruiting

  • Scientia Clinical Research LTD

    Randwick, New South Wales, Australia · Active not recruiting

  • Macquarie Clinical Trials Unit

    Sydney, New South Wales, Australia · Active not recruiting

  • Integrated Clinical Oncology Network Pty Ltd (Icon)

    South Brisbane, Queensland, Australia · Active not recruiting

  • Monash Health

    Melbourne, Victoria, Australia · Active not recruiting

  • The first affiliated hospital of Bengbu medical college

    Bengbu, Anhui, China · Recruiting

Showing 40 of 102 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.